All Metrics
GSK Valuation Metrics
GSK Stock Price Metrics
GSK Dividend Metrics
GSK Growth Rate Metrics
GSK Discounted Cash Flow Metrics
| Fair Value Price | $309.54 |
| Margin of Safety | 489.60% |
GSK Revenue Metrics
GSK PE Ratio Metrics
| PE Ratio | 11.62 |
| PE Ratio Avg TTM | 14.97 |
| PE Ratio Avg 3Y | 15.01 |
| Current VS TTM Avg | -22.38% |
| Current VS 3Y Avg | -22.57% |
| Current VS 5Y Avg | -9.52% |
GSK PS Ratio Metrics
| PS Ratio | 2.42 |
| PS Ratio Avg TTM | 2.00 |
| PS Ratio Avg 3Y | 2.10 |
| Current VS TTM Avg | +21.23% |
| Current VS 3Y Avg | +15.36% |
| Current VS 5Y Avg | +17.25% |
GSK PB Ratio Metrics
| PB Ratio | 3.44 |
| PB Ratio Avg TTM | 3.11 |
| PB Ratio Avg 3Y | 3.61 |
| Current VS TTM Avg | +10.46% |
| Current VS 3Y Avg | -4.60% |
| Current VS 5Y Avg | -2.39% |
GSK Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 12.71 |
| PFCF Ratio Avg TTM | 13.00 |
| PFCF Ratio Avg 3Y | 13.63 |
| Current VS TTM Avg | -2.24% |
| Current VS 3Y Avg | -6.74% |
| Current VS 5Y Avg | +7.26% |
GSK Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 1.07 |
| Debt/Equity Ratio Avg TTM | 1.14 |
| Debt/Equity Ratio Avg 3Y | 1.23 |
| Current VS TTM Avg | -6.76% |
| Current VS 3Y Avg | -13.10% |
| Current VS 5Y Avg | -28.58% |
GSK PEG Ratio Metrics
| PEG Ratio | 0.02 |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 0.02 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | -86.67% |
GSK FCF Yield
| FCF Yield | 7.87% |
| FCF Yield Avg TTM | 7.60% |
| FCF Yield Avg 3Y | 7.65% |
| Current VS TTM Avg | +3.49% |
| Current VS 3Y Avg | +2.90% |
| Current VS 5Y Avg | -18.71% |
GSK Earnings Yield
| Earnings Yield | 8.61% |
| Earnings Yield Avg TTM | 6.96% |
| Earnings Yield Avg 3Y | 6.52% |
| Current VS TTM Avg | +23.78% |
| Current VS 3Y Avg | +32.08% |
| Current VS 5Y Avg | +24.64% |
GSK EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 11.85 |
| Ev/Ebit Ratio Avg TTM | 12.44 |
| Ev/Ebit Ratio Avg 3Y | 13.81 |
| Current VS TTM Avg | -4.72% |
| Current VS 3Y Avg | -14.17% |
| Current VS 5Y Avg | -15.86% |
GSK EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 8.62 |
| Ev/Ebitda Ratio Avg TTM | 9.29 |
| Ev/Ebitda Ratio Avg 3Y | 9.73 |
| Current VS TTM Avg | -7.19% |
| Current VS 3Y Avg | -11.39% |
| Current VS 5Y Avg | -11.00% |
GSK EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.22 |
| Ev/Assets Ratio Avg TTM | 1.05 |
| Ev/Assets Ratio Avg 3Y | 1.11 |
| Current VS TTM Avg | +16.16% |
| Current VS 3Y Avg | +9.95% |
| Current VS 5Y Avg | +14.98% |
GSK EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.04 |
| Ev/Sales Ratio Avg TTM | 2.61 |
| Ev/Sales Ratio Avg 3Y | 2.69 |
| Current VS TTM Avg | +16.61% |
| Current VS 3Y Avg | +12.94% |
| Current VS 5Y Avg | +11.10% |
GSK Current Ratio Metrics
| Current Ratio | 0.79 |
| Current Ratio Avg TTM | 0.84 |
| Current Ratio Avg 3Y | 0.86 |
| Current VS TTM Avg | -5.33% |
| Current VS 3Y Avg | -7.46% |
| Current VS 5Y Avg | -8.19% |
GSK Quick Ratio Metrics
| Quick Ratio | 0.52 |
| Quick Ratio Avg TTM | 0.55 |
| Quick Ratio Avg 3Y | 0.58 |
| Current VS TTM Avg | -6.21% |
| Current VS 3Y Avg | -11.20% |
| Current VS 5Y Avg | -13.05% |
GSK ROIC Metrics
| ROIC | 16.61% |
| ROIC Avg 3Y | 12.53% |
| ROIC Avg 5Y | 10.40% |
| Current VS 3Y Avg | +32.59% |
| Current VS 5Y Avg | +59.74% |
| Current VS 10Y Avg | +63.92% |
GSK Return on Assets Metrics
| ROA | 9.37% |
| ROA Avg TTM | 6.85% |
| ROA Avg 3Y | 11.28% |
| Current VS TTM Avg | +36.79% |
| Current VS 3Y Avg | -16.93% |
| Current VS 5Y Avg | +3.27% |
GSK Return on Equity Metrics
| ROE | 34.96% |
| ROE Avg TTM | 26.90% |
| ROE Avg 3Y | 55.97% |
| Current VS TTM Avg | +29.96% |
| Current VS 3Y Avg | -37.54% |
| Current VS 5Y Avg | -23.50% |
GSK Net Profit Margin Metrics
| Net Profit Margin | 22.77% |
| Net Profit Margin Avg TTM | 18.68% |
| Net Profit Margin Avg 3Y | 14.86% |
| Current VS TTM Avg | +21.92% |
| Current VS 3Y Avg | +53.19% |
| Current VS 5Y Avg | +43.63% |
Last Updated: Saturday, June 27, 2026
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels